deltatrials
Completed OBSERVATIONAL NCT05201053

Acute Pancreatitis and Coagulation Study (APK)

Coagulation Disturbances and Thrombosis in Acute Pancreatitis (Koagulopati Och Trombos Vid Akut Pankreatit-APK Studien)

Sponsor: Lund University

Updated 6 times since 2022 Last updated: Apr 27, 2026 Started: May 1, 2017 Primary completion: May 31, 2022 Completion: Jun 1, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Pancreatitis, this trial is completed. The trial is conducted by Lund University and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

Inclusion criteria: Patients with acute pancreatitis admitted to Skåne University Hospital in Malmö Acute pancreatitis is defined as minimum 2 out of following: amylase levels \>3 times upper reference limit, clinical signs of acute pancreatitis, imaging findings of acute pancreatitis) Exclusion criteria: \<18 years of age \>72 hours from onset of symptom until first sampling Patients with immunosuppression or autoimmune diseases are excluded from som parts of the study. Methods: Serum and plasma is sampled repeatedly during the hospital admission. Pre defined protocols are used for data collections of relevant clinical information. Specific aspects of inflammation, thrombin generation, platelet function and Microparticles will be analysed in serum or plasma during the first consecutive days of acute pancreatitis. Biomarkers for severe disease as well as correlation between inflammation and coagulopathy will be investigated.

Inclusion criteria:

Patients with acute pancreatitis admitted to Skåne University Hospital in Malmö

Acute pancreatitis is defined as minimum 2 out of following: amylase levels \>3 times upper reference limit, clinical signs of acute pancreatitis, imaging findings of acute pancreatitis)

Exclusion criteria:

\<18 years of age

\>72 hours from onset of symptom until first sampling

Patients with immunosuppression or autoimmune diseases are excluded from som parts of the study.

Methods: Serum and plasma is sampled repeatedly during the hospital admission. Pre defined protocols are used for data collections of relevant clinical information.

Specific aspects of inflammation, thrombin generation, platelet function and Microparticles will be analysed in serum or plasma during the first consecutive days of acute pancreatitis.

Biomarkers for severe disease as well as correlation between inflammation and coagulopathy will be investigated.

Status Flow

~Feb 2022 – ~May 2024 · 27 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~May 2026 · 8 months · monthly snapshotCompletedMay 4, 2026 – present · 4 months · daily API

Change History

6 versions recorded
  1. May 4, 2026 — Present [daily]

    Completed

  2. Sep 2025 — May 2026 [monthly]

    Completed

  3. Sep 2024 — Sep 2025 [monthly]

    Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Completed

  5. May 2024 — Jul 2024 [monthly]

    Completed

    Status: RecruitingCompleted

Show 1 earlier version
  1. Feb 2022 — May 2024 [monthly]

    Recruiting

    First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

The study aims to investigate pathophysiological changes in coagulation in relation to inflammation in patients with acute pancreatitis. Serum and plasma is sampled repeated days from admission. Analysis will be done after recruitment. Specific biomarkers accuracy for prediction of moderate and severer acute pancreatitis will be calculated.

Contact Information

Sponsor contact:
  • Lund University
  • Region Skane
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations